Privigen, Immune Globulin Intravenous (Human) – Association of Hemolysis Following Administration and Related Labeling Update
Cases of hemolysis, some complicated by renal failure and disseminated intravascular coagulation, have been reported following the administration of Privigen. Risk factors for hemolysis include the use of high doses, a non-O blood group and possibly an underlying inflammatory state.
Health Canada RSS – MedEffect Canada – Advisories and Recalls for Health Professionals
Category: MedEffect Canada